LAB INTERNATIONAL COMPLETES PATIENT ENROLLMENT IN FENTANYL TAIFUN TRIAL

A A

LAB International has completed patient enrollment for the pivotal Phase IIa trial of its lead product, Fentanyl Taifun.

The multicenter, randomized, double blind, placebo-controlled Phase II trial is investigating the efficacy and safety of Fentanyl Taifun for the treatment of breakthrough cancer pain, monitoring response at different Fentanyl doses. The trial enrolled a total of 122 cancer patients on maintenance opioid therapy for persistent pain.